MITAC-COMPUTING
27.5.2019 04:02:06 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, will be exhibiting a full line of HPC, storage and cloud computing server platforms that are optimized for HPC, enterprise and datacenter markets at Computex 2019 from May 28th to June 1st , Booth # L0631a in Taipei, Taiwan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005002/en/
“The increasingly growing demand for AI is transforming the data center and is resulting in a tremendous amount of data being pulled into big data platforms at massive scale,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s leading portfolio of HPC, storage and cloud server platforms are based on the 2nd gen Intel® Xeon® Scalable processors and are designed to help enterprises and data center service providers capture, process, and analyze big data faster and at a more powerful rate than ever before.”
2nd Gen Intel Xeon Scalable Processors Empower TYAN HPC and Storage Platforms to Deliver Leading Performance
TYAN’s HPC and storage server platforms are built on the 2nd gen Intel Xeon Scalable processors with accompanying new innovations of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable faster machine learning application execution and accelerated workload processing and service delivery. The new Thunder HX FT83-B7119 is an AI-optimized platform and is ideal for AI training and inference applications. The system supports for up to 3TB of memory and 12 hot-swappable 3.5” drives in a 4U enclosure.
The Thunder SX FA100-B7118 is TYAN’s flagship storage server supporting dual-socket 2nd gen Intel Xeon Scalable processors and 100 3.5” drives in a 4U rackmount form factor. The platform is designed for both cold storage and large-scale object storage applications such as Lustre. TYAN’s Thunder SX TN76-B7102 is 2U dual-socket 2nd gen Intel Xeon Scalable processor-based storage platform. With support for up to 24 DDR4 DIMM slots and maximum expansion up to 8 standard PCIe slots, the TN76-B7102 can fully address the high memory capacity required by data virtualization and in-memory databases.
For the high-performance storage segment, the Thunder SX GT62H-B7106 is a 1U server platform with support hot-swap all-flash drives. The GT62H-B7106 features dual-socket 2nd gen Intel Xeon Scalable processors, 16 DIMM slots, two low profile PCIe x16 slots, and 10 U.2 NVMe drive bays. This platform offers maximum storage performance and large memory capacity and is ideal for edge server applications.
The new Thunder SX GT90-B7113 features support for dual 2nd gen Intel Xeon Scalable processors, 12 hot-swap 3.5” drives mounted to a service drawer and 4 hot-swap NVMe U.2 drive bays in a 35” deep 1U chassis. The platform perfectly matches CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
Intel ® Xeon ® D-2100 and Intel ® Xeon ® E-2100 Processor-based Platforms to Maximize Compute Performance and Efficiency for Cloud and Storage
Powered by the Intel Xeon D-2100 processors, TYAN Thunder SX TE70-B5546 and Thunder SX TE73-B5546 platforms are optimized to deliver rich features of low-power, high-density and high-availability. These two systems are both in 2U dual-node form factor with dual-controller, dual-path redundant design for high availability requirement and support dual-port SAS/NVMe storage functions for today’s high available data-intensive storage environments. TE70-B5546 supports up to 24 2.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2; TE73-B5546 supports up to 12 3.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2.
Moreover, taking full advantage of Intel Xeon E-2100 processors, TYAN offers increased reliability, security, performance, and affordability for its entry server lineup. TYAN’s Thunder CX GT24E-B5556 is a 1U single-socket Intel Xeon E-2100 processor-based edge cloud server. With support for up to 4 DDR4 DIMM slots, 3 PCIe slots, and dual 10GBase-T Ethernet ports, the platform is optimized for cost-effective cloud gaming applications. The Thunder CX GX38-B5550 is 1U single-socket Intel Xeon E-2100 processor-based compact sever with shallow chassis and support for 2 3.5” internal SATA drive bays for IoT applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190526005002/en/
Contact:
MiTAC Computing Technology Corporation/ TYAN Business Unit Fenny Chen fenny.chen@tyan.com.tw
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom